We scan new podcasts and send you the top 5 insights daily.
Chris Moxham says traditional de novo discovery costs about $25 million to reach an IND. Transcripta instead builds a tiered pipeline with novel molecules, clinical-stage assets already de-risked, and approved drugs repurposed for new indications, aiming for a more capital-efficient company. This mix reduces reliance on one costly path.
Recursion's CEO outlines a two-pronged pipeline strategy. The first prong uses phenomics to uncover novel biological insights for new targets, like their FAP program. The second uses their AI-driven small molecule design platform to improve the therapeutic index for known but historically 'hard-to-drug' targets, like CDK7. This balanced portfolio approach de-risks development by leveraging different strengths of their end-to-end platform.
Clayton Mellina says Transcripta builds disease signatures from patient single-cell RNA-seq, then screens drugs in cells to create its Drug Gene Atlas. It matches those signatures before committing to one protein target, keeping target identification open until later and widening the therapeutic search. Chris Moxham adds this combines phenotypic screening with efficient target-based work.
To reduce risk, Nuago prioritizes cancers based on two criteria: high unmet medical need and the existence of clinically validated delivery methods for that specific tissue. This strategy separates their novel drug science from novel delivery science, allowing them to focus resources on proving their mechanism without inventing a delivery system.
To manage risk, Metaphor focuses its internal pipeline on known, validated biological mechanisms rather than pursuing novel biology. Their innovation lies in creating highly differentiated molecules for these proven targets—a chemistry and engineering challenge, not a biological discovery one.
Biotech companies create more value by focusing on de-risking molecules for clinical success, not engineering them from scratch. Specialized platforms can create molecules faster and more reliably, allowing developers to focus their core competency on advancing de-risked assets through the pipeline.
Adcytherix selects its novel ADC payloads from drugs already approved for cancer treatment. This innovative strategy ensures the payload has a known, positive therapeutic index from the start, making the resulting ADC potentially safer and more tolerable than those using ultra-potent toxins with no established safety window in humans.
A drug that is proven safe in humans but fails to show efficacy for its initial target is not a total loss. It's a de-risked asset with a known safety profile, making it a prime, low-risk candidate for repurposing into a new disease area, especially for rare diseases with orphan drug protections.
Lyora Therapeutics' model is built on acquiring promising, pre-clinically validated programs that larger companies shelved due to strategic shifts. This "asset-driven" approach allows a new company to rapidly build a pipeline without the cost and time of early-stage discovery, capitalizing on the sunk R&D costs of former owners.
Ambrose's large Series A for Narydronate, a drug already approved in Italy for other uses, highlights a capital-efficient R&D model. By targeting a new rare disease, the company leverages existing safety data to jump directly to a pivotal Phase 3 trial, attracting significant investment for a de-risked asset.
Ipsen avoids the high-risk, capital-intensive phase of basic research. Instead, its R&D strategy focuses on licensing promising drug candidates from universities and biotechs. The company then leverages its expertise in later-stage development, including toxicology, manufacturing scale-up (CMC), and clinical trials, to bring these de-risked assets to market.